RAPIvD strengthens ties with Stream Bio

News Release

07:02:2023

for immediate release

RAPIvD strengthens ties with Stream Bio

Rapid in vitro diagnostics specialist, RAPIvD Ltd has signed a partnership agreement with Stream Bio to use their conjugated polymer nanoparticles (CPNs) in lateral flow assay development projects.

Stream Bio’s CPNs provide an alternative to traditional conjugates such as gold nanoparticles. Tests have demonstrated the superior sensitivity over gold and are supplied in a range of colours in the visible, ultra-violet and infra-red spectrums. The colour options unlock new and more intuitive ways to use lateral flow technology, including easy-read multiplex strips, qualitative tests and tests for low-light environments.

The partnership agreement sees RAPIvD offering Stream Bio CPNs in lateral flow assay development. Stream Bio will offer RAPIvD’s range of services in developing and improving assays for companies requiring diagnostic devices.

RAPIvD CEO, Dr Robert Porter said. “We’ve been working with the team at Stream Bio for some time and considered them to be a part of our collaborative network. We’ve now moved from an informal relationship to a semi-formal partnership.

“We don’t enter such partnerships lightly. I would only suggest using products and services that I am convinced will improve what we do. We developed an assay for one of Stream Bio’s customers and immediately wanted to make their technology available to our customers too. The combination of high sensitivity and colours expands the application of lateral flow technology, so I’m looking forward to the type of projects that we can offer moving forward”.

Stream Bio CEO, Andy Chaloner commented. “The guys at RAPIvD are leaders in rapid in vitro diagnostic development, so to be able to offer their services to our clients benefits everyone. Rob and I have discussed a more structured relationship and the ease with which this was achieved proves that we are on the same page. We’ve got a great product to complement RAPIvD’s services and their reach will help to convince more companies to look at alternatives to gold in their lateral flow assays.”

Ends.